Pikralida sp. z o.o. is currently working on four R&D projects co-financed with national and European funds.
Project no. POIR.01.01.01-00-0235/20
Utilisation of a matrix metalloprotease inhibitor to create an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
Project no. POIR.01.01.01-00-0235/20
Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
Project no. TANGO-IV-C/0012/2019
Development of an innovative combined preparation dedicated to the treatment of hypertension.
Project no. POIR.04.01.04-00-0063/20-00
Development of an innovative combination drug formulation dedicated for geriatric patients in pain pharmacotherapy providing optimal effectiveness and safety of the pharmacotherapy.
Project no. RPWP.01.02.00-30-0047/19-00
Establishment of R&D laboratories for supergeneric drugs.
Project no. POIR.01.01.01-00-0235/20
Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
Project no.TANGO-IV-C/0012/2019
Development of an innovative combined preparation dedicated to the treatment of hypertension.
Project no POIR.01.01.01-00-0235/20
Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
Project no. POIR.04.01.04-00-0063/20-00
Development of an innovative combination drug formulation dedicated for geriatric patients in pain pharmacotherapy providing optimal effectiveness and safety of the pharmacotherapy.
Project no. RPWP.01.02.00-30-0047/19-00
Establishment of R&D laboratories for supergeneric drugs.
